Question
Does a laboratory’s insurance automatically cover new tests added to the menu?
Short answer
Often yes for a like-for-like addition, and not reliably for anything that changes the character of the work. Your programme was underwritten against a described scope of operations. Adding a materially different test, especially a laboratory developed test or one supporting a treatment decision, can move you outside what was described, and most policies impose a duty to report material changes during the term rather than at renewal.
The principle, which is not lab specific
An insurance programme is priced and worded against a description of what you do. When what you do changes materially mid-term, two things can happen: the cover may not extend to the new activity, and the change may itself be reportable under the policy.
Most life sciences operators think of insurance as an annual event. It is more accurate to treat a material change in operations as its own trigger, in the same way a new contract or a funding round is.
What counts as routine and what does not
Adding another analyte to an existing validated platform, using the same methodology, for the same clinical purpose, is usually within the scope already described. This is not a call your broker needs to make every quarter.
What tends to matter is a change in kind rather than volume. Bringing a test in house that you previously sent out. Launching a laboratory developed test rather than running an approved assay. Moving from a screening or wellness context into a result that will directly drive a treatment decision. Adding a new specimen type, a new platform, or genetic and molecular work where interpretation carries far more weight than the instrument reading.
Why the professional liability line is the sensitive one
Diagnostic professional liability is priced against the consequence of being wrong. A test whose result changes a treatment decision carries a different consequence than one that does not, even where the laboratory workload looks similar.
Laboratory developed tests deserve particular attention because responsibility for the design and validation of the test sits with the laboratory rather than with a manufacturer, which concentrates the exposure rather than sharing it.
How to handle it without creating busywork
Set a standing rule instead of case-by-case judgement: any new test category, platform, specimen type, or clinical use gets a short note to the broker before it goes live. Volume growth within the existing description does not.
Keep the validation record, because it is what an underwriter will ask for and what a claim will be defended on. And check whether the policy is claims-made, since with claims-made cover what matters is the scope in force when the claim is made, not when the test was run.
The wider version of this principle applies across the sector: a new geography, a new service line, or a new software release can each be a material change. Geography in particular is covered separately in the international coverage material.
Primary sources
Sources and references
This answer draws on the following regulatory, statutory, and standards-body sources. Coverage availability and program structure also depend on carrier appetite and underwriter discretion not captured by these sources.
- FDA - Laboratory Developed Testshttps://www.fda.gov/medical-devices/in-vitro-diagnostics/laboratory-developed-tests
- CMS - Clinical Laboratory Improvement Amendments (CLIA)https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
Related practice areas
Insurance clauses in this area
Related questions
Have a more specific question?
A specialist will reach out by the end of the day.
Request a free coverage review